EVSC SOMEONE KNOWS SOMETHING  This is from Nov 02

EVSC SOMEONE KNOWS SOMETHING >>  This is from Nov 02,2012~ "Endovasc Inc" was a vendor along with the other Giants........

Global Drug-eluting Stents Market 2011-2015: The Global Drug-Eluting Stents Market to Reach US$6,278 Million By 2015 M2 Communications "M2 PressWIRE" 
Dublin - Research and Markets ( http://www.researchandmarkets.com/research/krv49d/global) has announced the addition of the "Global Drug-eluting Stents Market 2011-2015" report to their offering. 

One of the key factors contributing to this market growth is the increasing incidence of cardiovascular diseases. The Global Drug-eluting Stents market has also been witnessing the use of bifurcated self-expanding coronary stents. However, the decline in the average selling price of drug-eluting stents could pose a challenge to the growth of this market. 

Key vendors dominating this market space include Abbott Laboratories , Boston Scientific Corp. , Johnson and Johnson , Medtronic Inc. , MicroPort Scientific Corp. , and Terumo Medical Corp. 

Other vendors mentioned in the report: Allvivo Vascular Inc. , Arterial Remodeling Technologies, Bayer MaterialScience , Biocompatibles Ltd. , Biosensors International Ltd. , Biotronik KG , Blue Medical, Cardiomind, Cook Medical Inc. , Devax Inc. , Endovasc Inc. , Goodman Co. Ltd. , InnoCore Technologies BV , Invatec, Lepu Medical Technology , MIV Therapeutics Inc. , PolyBioMed, Reva Medical Inc. , Stentys SA , SurModics Inc. , Translumina GmbH , X-Cell Medical Inc. and Xtent Inc.

Commenting on the report, an analyst from TechNavio's Healthcare team said: "Medical tourism is becoming popular globally because of the low-cost procedures in developing countries. Patients from the US and Europe visit countries such as the Philippines , India and China for percutaneous transluminal coronary angioplasty (PTCA) procedures and save around 60-70 percent of the treatment cost. Most of the implants from developed countries are now available in developing countries, and some indigenous manufacturers are offering Drug-eluting Stents (DES) at competitive prices. This attracts overseas patients to seek treatment in developing countries. This increasingly popular trend is expected to have a high impact on the market during the forecast period." 

According to the report, one of the main drivers is the global increase in the aging population. Lower mortality rates, increased life expectancy, and population control in developing countries such as China , India and Japan have resulted in an increase in the aging population. The global aging population is expected to increase massively by 2050. The increase in the aging population results in an increase in PTCA surgeries. This in turn leads to increased use of DES, propelling the growth of the Global DES market. 

Further, the report discusses that one of the major challenges in the Global DES market is the decline in the average selling price of DES. 

For more information visit  http://www.researchandmarkets.com/research/krv49d/global

CONTACT: 

Research and Markets , 

Laura Wood , 

Senior Manager. 

press@researchandmarkets.com 

Fax from USA : 646-607-1907 

Fax from rest of the world: +353-1-481-1716 

Sector: Stents ( http://www.researchandmarkets.com/categories....id=krv49d)

(( M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at  http://www.presswire.net on the world wide web. Inquiries to info@m2.com)).